Quick decision summary
Mounjaro (tirzepatide) generally produces more weight loss on average than Wegovy (semaglutide), around 20% over six months at the top dose versus around 12 to 15% over 12 months for Wegovy, when paired with lifestyle support. Mounjaro activates two gut-hormone receptors at once (GLP-1 and GIP). Wegovy activates one (GLP-1). The dual mechanism is part of why average weight loss with Mounjaro is higher. Wegovy has the deeper long-term outcome data, especially the SELECT trial, which shows cardiovascular event reduction in patients with established cardiovascular disease and overweight or obesity. Wegovy is also FDA-approved for adolescents aged 12 and older, while Mounjaro is approved for adults aged 18 and older. The medication price is also different: Wegovy starts at around AED 743.5 per month at the lowest dose (0.25 mg) and rises to around AED 1,712 per month at the highest dose available in the UAE (2.4 mg), while Mounjaro is AED 1,734 per month at every dose. The right choice depends on the patient.
Key takeaways:
- Mounjaro is a dual GLP-1 / GIP receptor agonist; Wegovy is GLP-1 only.
- Mounjaro typically delivers higher average weight loss in trials (around 20% vs 12 to 15%).
- Wegovy has stronger long-term cardiovascular evidence from the SELECT trial.
- Wegovy is FDA-approved for adolescents 12 and older. Mounjaro is approved for adults 18 and older only.
- Wegovy medication price in the UAE starts at around AED 743.5 per month at the lowest dose and rises to around AED 1,712 per month at the highest dose. Mounjaro is AED 1,734 per month at every dose, the unified UAE price.
- The decision is matched to the patient’s medical picture, not declared as a class-wide winner.
How they differ at the molecular level
Both medications belong to the same family of gut-hormone medications, but they do not act in exactly the same way.
- Wegovy contains semaglutide. It is a GLP-1 receptor agonist that mimics the natural GLP-1 hormone released after a meal. It slows stomach emptying, reduces appetite, and improves the body’s insulin response. Semaglutide is also the active ingredient in Ozempic (licensed for type 2 diabetes) and Rybelsus (a daily oral tablet for type 2 diabetes).
- Mounjaro contains tirzepatide. It is a dual GLP-1 / GIP receptor agonist, meaning it activates two natural gut-hormone receptors at the same time. GIP (glucose-dependent insulinotropic polypeptide) is the second receptor. Activating both is believed to deliver a stronger effect on appetite, blood sugar, and energy regulation than activating GLP-1 alone. See also Mounjaro prescribing information.
The dual mechanism is the structural reason Mounjaro generally outperforms Wegovy on average weight loss. The active component in Wegovy (semaglutide) has been around for much longer than tirzepatide, so Wegovy has more accumulated long-term evidence, including the SELECT cardiovascular outcome data. Read more on semaglutide as a molecule and tirzepatide as a molecule.
Eligibility: who can take each medication
There is one important differentiator between Wegovy and Mounjaro on eligibility that often gets missed.
- Wegovy is FDA-approved for adolescents aged 12 and older, in addition to adults. This makes it an option in carefully selected paediatric and adolescent obesity cases, under specialist supervision.
- Mounjaro is FDA-approved for adults aged 18 and older only. It is not approved for adolescents.
For adults, both medications have similar BMI-based eligibility (BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition such as hypertension, dyslipidaemia, polycystic ovarian syndrome, or sleep apnoea). The adolescent indication is a real differentiator that affects which families can be offered which medication.
Average weight-loss results: what the trials show
The figures below come from each medication’s pivotal trial. They are useful as a frame, not as a promise.
- Wegovy (semaglutide 2.4 mg, weekly). The STEP 1 trial in NEJM reported an average weight loss of around 15% over 68 weeks when paired with structured lifestyle support.
- Mounjaro (tirzepatide 15 mg, weekly). The SURMOUNT-1 trial in NEJM reported an average weight loss of around 20% over 72 weeks at the highest dose.
In real-world practice at Endocare, we often see significantly better outcomes with both Mounjaro and Wegovy than the published trial averages, because of the combination of medication with structured lifestyle coaching. Our patients commonly achieve 15 to 20% weight loss when they engage with the full programme.
The same caveats apply to all of these numbers. Individual results vary by adherence, dose tolerance, lifestyle support, and underlying biology. Some patients lose more than the average. Others lose less.
Side-effect profiles compared
Both medications share the GLP-1 class side-effect family.
- Most common: nausea, mild reflux, reduced appetite, constipation or diarrhoea. Not every patient experiences them. When they appear, they can be particularly pronounced in the first few days at a new dose and usually settle within the first 2 weeks at that step.
- Less common but real: hair shedding linked to rapid weight loss and nutrient gaps; dehydration if intake drops sharply.
In clinical practice, the side-effect intensity overlaps significantly. Some patients tolerate Mounjaro more easily than Wegovy. Others tolerate Wegovy more easily than Mounjaro. There is no single ‘gentler’ medication across all patients, which is part of why dose titration in conversation with the specialist, nutrition coaching, and active follow-up matter more than the brand choice.
Wegovy vs Mounjaro at a glance
| Feature | Wegovy (semaglutide) | Mounjaro (tirzepatide) |
| Receptor | GLP-1 only | GLP-1 and GIP (dual) |
| Average weight loss | Around 12 to 15% at 12 months | Around 20% at 6 months |
| Eligibility | Adults and adolescents 12+ | Adults 18+ only |
| Long-term cardiovascular evidence | Strong (SELECT trial) | Still emerging |
| Dose range available in UAE (weekly) | 0.25 to 2.4 mg | 2.5 to 15 mg |
| Medication price in UAE (per month) | From around AED 743.5 (0.25 mg) up to around AED 1,712 (2.4 mg) | AED 1,734 at every dose |
| Delivery from Endocare | Free across UAE | Free across UAE |
When the answer is Wegovy
There are clear patient patterns where Wegovy is the better recommendation, not just an alternative.
- Patients with established cardiovascular disease and overweight or obesity. Wegovy’s SELECT trial provides direct cardiovascular outcome data that Mounjaro does not yet match.
- Adolescent patients aged 12 to 17, where Wegovy is the FDA-approved option and Mounjaro is not.
- Patients who have already responded well to semaglutide at a lower dose, where staying within the same molecule and titrating up makes more sense than switching mechanisms.
- Patients who prefer the deeper long-term experience base. Semaglutide has been in widespread use for longer than tirzepatide.
Read more on Wegovy at Endocare.
When the answer is Mounjaro
There are equally clear patterns where Mounjaro is the better recommendation.
- Patients in higher BMI categories or with significant obesity-related complications, where the largest possible weight loss is the medical priority.
- Patients with type 2 diabetes alongside obesity, where the strong glucose-lowering effect of tirzepatide is clinically useful.
- Patients who tolerated semaglutide poorly and may respond better to the dual-receptor mechanism, although tolerability cannot be guaranteed.
- Patients for whom the higher magnitude of average weight loss is needed to support meaningful improvement in conditions such as sleep apnoea, severe insulin resistance, or non-alcoholic fatty liver disease.
Read more on Mounjaro at Endocare.
Medication cost at the UAE pharmacy
This section is about the medication price at the pharmacy, not any Endocare treatment package.
- Wegovy: starts at around AED 743.5 per month at the 0.25 mg dose and rises to around AED 1,712 per month at the 2.4 mg highest dose available in the UAE. The price varies by dose.
- Mounjaro: AED 1,734 per month at every dose, from 2.5 mg up to 15 mg. This is the unified Mounjaro medication price across the UAE.
Medication delivery from Endocare is free across the UAE, with same-day delivery in Dubai and within 48 hours nationwide. Endocare does not add markup to the official pharmacy price. Patients in Dubai can read more about Wegovy in Dubai on the dedicated city service page.
Switching from one to the other
Switching between Wegovy and Mounjaro is a clinical decision, taken in clinic with a clear reason and a clear plan. Patients sometimes switch for financial reasons, for example starting on Wegovy at the lower doses and switching to Mounjaro as Wegovy becomes more expensive at higher doses, or the other way around. Other patients switch because of a plateau, a tolerability issue, or a change in goals. The new medication is started at its appropriate starting point and titrated up under specialist supervision, with clear monitoring. Doses do not transfer one-to-one between molecules.
For readers who also want Ozempic context, see the three-way comparison with Ozempic.
Where Foundayo fits
Wegovy and Mounjaro are not the only options at Endocare, and the choice between them is not the only conversation. For patients who do not want or cannot tolerate an injection, Foundayo oral GLP-1 pill is a daily oral GLP-1 pill now available in the UAE. If the appropriate answer for a patient is neither Wegovy nor Mounjaro, the endocrinologist will say so during the consultation.
Frequently asked questions
Is Mounjaro better than Wegovy?
On average weight loss, Mounjaro generally outperforms Wegovy in trials (around 20% vs 12 to 15%). ‘Better’ depends on the patient. For magnitude of weight loss alone, Mounjaro often wins. For deeper long-term cardiovascular evidence, Wegovy wins. For adolescent patients aged 12 and older, Wegovy is the FDA-approved option. The right answer depends on the medical picture.
Can I switch from Wegovy to Mounjaro?
Yes, after a clinical review. Common reasons to switch include a plateau on Wegovy 2.4 mg, tolerability issues, cost considerations as Wegovy gets more expensive at higher doses, or a change in goals or comorbidities. Switching is planned by the endocrinologist with a clear starting dose and titration on the new medication.
Which has fewer side effects?
Both share the GLP-1 class side-effect family. In practice, some patients tolerate Mounjaro more easily; others tolerate Wegovy more easily. There is no single ‘gentler’ option for everyone. Dose titration, nutrition coaching, hydration, and active follow-up matter more than the brand choice for keeping side effects manageable.
Which is better for PCOS?
Both are used in patients with polycystic ovarian syndrome and obesity. The choice depends on the patient’s BMI, insulin resistance picture, fertility plans, and overall medical history. Pregnancy planning is a particular consideration, because GLP-1 medications are stopped before pregnancy. A structured consultation with the endocrinologist is the right step. When the patient profile is around polycystic ovarian syndrome, Endocare’s Mounjaro for PCOS eligibility article goes into the nuances.
Which is better for type 2 diabetes?
For type 2 diabetes specifically, Mounjaro’s dual mechanism produces strong glucose-lowering effects in addition to weight loss. Wegovy is licensed for chronic weight management; for diabetes, the semaglutide product used is Ozempic – see also our Ozempic vs Wegovy comparison. For a wider three-way view, see the three-way comparison.
Final word from Endocare
Wegovy and Mounjaro are both excellent medications. The honest framing is that they are not interchangeable, and the better one for a given patient depends on the patient. Magnitude of weight loss, cardiovascular profile, eligibility (including the adolescent indication for Wegovy), tolerability, medication cost, and goals all feed into the recommendation. If you are weighing the two, the next step is a comparison consultation. The point is not to declare a winner. The point is to choose the right medication for you.
Book a comparison consultation at Endocare in Dubai or Abu Dhabi. The endocrinologist will review your medical history, body-composition analysis, and goals, then recommend the option that fits your full clinical picture.
